Form 8-K - Current report:
SEC Accession No. 0001213900-25-023733
Filing Date
2025-03-13
Accepted
2025-03-13 16:40:07
Documents
16
Period of Report
2025-03-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0234319-8k_pluriinc.htm   iXBRL 8-K 41087
2 FORM OF SHARE PURCHASE AGREEMENT ea023431901ex10-1_pluriinc.htm EX-10.1 273306
3 FORM OF ASSIGNMENT AND ASSUMPTION AGREEMENT ea023431901ex10-2_pluriinc.htm EX-10.2 12688
4 FORM OF LEAK-OUT AGREEMENT ea023431901ex99-1_pluriinc.htm EX-99.1 15351
  Complete submission text file 0001213900-25-023733.txt   594638

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE plur-20250312.xsd EX-101.SCH 3030
6 XBRL LABEL FILE plur-20250312_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE plur-20250312_pre.xml EX-101.PRE 22369
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0234319-8k_pluriinc_htm.xml XML 3680
Mailing Address MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 HAIFA L3 3508409
Business Address MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 HAIFA L3 3508409 972-74-710-7171
Pluri Inc. (Filer) CIK: 0001158780 (see all company filings)

EIN.: 980351734 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-31392 | Film No.: 25736435
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)